Pure Selank peptide therapy in laboratory literature refers to the experimental investigation of synthetic Selank—a heptapeptide derivative of the endogenous immunomodulator tuftsin—in animal models and cellular assays. Researchers study Selank for its distinct interactions with GABAergic neurotransmission, neurotrophic factor expression, and peripheral immune pathways. This reference manual outlines the molecular structure, preclinical findings, handling protocols, and analytical verification standards required for rigorous scientific inquiry.
Pure Selank peptide therapy in laboratory literature refers to the experimental investigation of synthetic Selank—a heptapeptide derivative of the endogenous immunomodulator tuftsin—in animal models and cellular assays. Researchers study Selank for its distinct interactions with GABAergic neurotransmission, neurotrophic factor expression, and peripheral immune pathways. This reference manual outlines the molecular structure, preclinical findings, handling protocols, and analytical verification standards required for rigorous scientific inquiry.
In contemporary preclinical literature, pure Selank peptide therapy describes the controlled administration of highly purified synthetic Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) within in vitro and in vivo laboratory models. Rather than referring to clinical administration, the term signifies standardized experimental paradigms designed to evaluate how this regulatory heptapeptide modulates central nervous system pathways, neurotransmitter metabolism, and systemic immune markers.
Synthesized by joining the endogenous tetrapeptide tuftsin with a Pro-Gly-Pro tripeptide sequence at its C-terminus, Selank exhibits enhanced metabolic stability against circulating peptidases compared to native tuftsin. When investigating pure Selank 10mg in controlled settings, researchers focus on isolating its specific biological activities without the confounding effects of structural degradation products or synthetic impurities. High-purity formulations ensure that measured biological responses—such as alterations in GABA receptor affinity or neurotrophic factor transcription—are directly attributable to the intact peptide sequence.
Selank was originally engineered to preserve the biological functionality of tuftsin (Thr-Lys-Pro-Arg)—a natural immunomodulatory peptide originating from the heavy chain of human immunoglobulin G (IgG)—while extending its enzymatic half-life in physiological media. Natural tuftsin rapidly degrades in serum due to cleavage by carboxypeptidases and aminopeptidases. By appending the C-terminal tripeptide sequence Proline-Glycine-Proline (PGP), structural biochemists created a synthetic analog with significantly elevated metabolic stability.
The molecular weight of Selank acetate is approximately 751.9 g/mol. The incorporation of the PGP motif protects the basic amino acid residues at the N-terminus from rapid proteolysis, allowing extended interaction with central and peripheral targets in animal models. Researchers examining our catalog of research peptides often analyze how structural modifications like PGP elongation alter peptide stability, receptor binding kinetics, and trans-epithelial transport mechanisms in preclinical assays.
Preclinical investigations demonstrate that Selank influences both gamma-aminobutyric acid (GABA) signaling and monoaminergic systems in rodent models. Radioligand binding studies suggest that Selank does not bind directly to the primary GABA recognition site on the GABA-A receptor complex. Instead, in vitro data indicate that Selank acts as an allosteric modulator, altering the affinity of specific GABA-A receptor subtypes for endogenous ligands and benzodiazepine binding site agonists.
Furthermore, animal studies demonstrate that administration of Selank leads to rapid changes in monoamine metabolism within specific brain structures, including the hippocampus, hypothalamus, and striatum. Preclinical data indicate transient increases in serotonin (5-HT) synthesis and metabolite concentration (5-HIAA), alongside alterations in dopamine turnover rates. These neurochemical shifts occur without the sedative or hypnotic actions typical of classical GABA-A receptor positive allosteric modulators, making Selank a valuable probe for dissecting distinct sub-circuits within the central nervous system. Detailed mechanism reports are curated in the PX1 preclinical research library.
In addition to classical neurotransmitter pathways, preclinical studies suggest that Selank significantly influences gene expression profiles associated with neuroplasticity and neuronal survival. Experimental rodent models treated with Selank show rapid up-regulation of Brain-Derived Neurotrophic Factor (BDNF) mRNA expression in the hippocampus. BDNF plays a central role in synaptogenesis, long-term potentiation (LTP), and neuronal maintenance.
Microarray and quantitative RT-PCR analyses reveal that Selank modulates the expression of dozens of genes involved in neurotransmission, ion channel regulation, and cellular signaling cascades within hours of administration. In vitro neuronal cultures exposed to Selank demonstrate altered transcript levels for specific GABA-A receptor subunits, suggesting a homeostatic regulatory mechanism that balances immediate receptor-level modulation with long-term genomic adaptation. Researchers studying neuroplasticity frequently cross-reference these transcriptomic datasets when designing comparative protocols.
To understand the distinct research utility of Selank, laboratory investigators frequently compare its activity profile against structurally or functionally related compounds within the regulatory peptide class. Primary comparative candidates include its parent peptide tuftsin and the ACTH-derived heptapeptide Semax.
While tuftsin peptide studies center primarily on macrophage activation and peripheral immune response, Selank exhibits dual activity spanning both immunomodulation and central nervous system modulation due to its extended plasma half-life. Compared to Semax research, which highlights melanocortin receptor engagement and brain-derived neurotrophic signaling driven by an ACTH 4-10 fragment core, Selank operates primarily through GABAergic allosteric pathways and serotonergic modulation. Evaluating these compounds side-by-side—including modified variants like N-Acetyl Semax Amidate—allows researchers to map distinct neuropeptide pathways involved in cellular stress responses and cognitive signaling models.
Inheriting the core sequence of tuftsin, Selank retains potent regulatory effects on immune system cells, which have been extensively documented in animal models and primary cell cultures. In vitro assays using human peripheral blood mononuclear cells (PBMCs) and rodent splenocytes indicate that Selank modulates the expression profile of key cytokines, including Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha).
Preclinical evidence demonstrates that Selank can alter the balance between Th1 and Th2 cytokine expression under conditions of experimental stress or inflammation. In models of induced immune suppression, Selank administration restores natural killer (NK) cell activity and phagocytic indices of neutrophils and macrophages. This dual neuro-immune regulatory potential makes pure Selank a critical tool for researchers investigating the complex crosstalk between the central nervous system and peripheral immune system.
Maintaining peptide integrity during reconstitution and storage is essential for obtaining reproducible experimental results. Pure Selank is typically supplied as a lyophilized (freeze-dried) cake or powder as a stable acetate salt. Unopened lyophilized vials should be stored at -20°C for short-to-medium term storage, or at -80°C for long-term preservation, protected from light and moisture exposure.
For laboratory reconstitution, researchers should adhere to sterile procedures within a laminar flow hood:
1. Allow the lyophilized vial to equilibrate to room temperature before reconstitution to prevent condensation inside the container.
2. Reconstitute using sterile, laboratory-grade solvents such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile Phosphate-Buffered Saline (PBS, pH 7.4), depending on the requirements of the planned assay.
3. Direct the solvent gently along the inner glass wall of the vial rather than shooting it directly onto the lyophilized cake.
4. Swirl the vial gently with a circular motion until fully dissolved. Never vortex high-purity peptides, as mechanical shear forces can induce peptide aggregation and conformational degradation.
5. Aliquot reconstituted solutions into sterile polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles, and store at -20°C or -80°C for subsequent experimental steps.
Reliable preclinical research requires raw materials verified by rigorous analytical methods. Impurities generated during solid-phase peptide synthesis (SPPS)—such as truncation sequences, deletion peptides, and side-chain protecting group adducts—can cause off-target cellular effects and confound experimental outcomes.
PX1 Research mandates strict quality control verification for every production lot:
- **Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC):** Verifies chemical purity levels, ensuring the target compound meets or exceeds 98.0% purity.
- **Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF MS) or ESI-MS:** Confirms exact molecular mass (751.9 Da for Selank core) and verifies sequence identity.
- **Endotoxin Testing (LAL Assay):** Ensures bacterial endotoxin levels remain below stringent thresholds (<0.05 EU/mg) to prevent non-specific inflammatory responses in cellular assays.
Every vial supplied by PX1 Research is backed by a lot-specific Certificate of Analysis (COA). Principal investigators and institutional buyers can establish wholesale lab accounts for bulk sourcing with guaranteed lot consistency and comprehensive analytical documentation.
In animal research, dosage paradigms for Selank vary significantly based on the species, route of administration, and specific physiological endpoint under evaluation. In rodent models (rats and mice), experimental protocols described in peer-reviewed literature generally utilize dosage ranges from 50 mcg/kg to 500 mcg/kg body weight.
Commonly documented routes of administration in animal research include intranasal instillation, intraperitoneal (IP) injection, and subcutaneous (SC) injection. Intranasal administration is particularly prominent in central nervous system research due to direct nose-to-brain transport pathways along the olfactory and trigeminal nerve routes, bypassing the blood-brain barrier. In contrast, in vitro cellular models typically apply Selank in concentrations ranging from 10 nM to 10 micromolar to assess immediate signal transduction events, receptor binding, and transcriptomic shifts.
What is pure Selank peptide therapy in a research context?
In preclinical research, pure Selank peptide therapy refers to the experimental study of synthetic Selank (a tuftsin-derived heptapeptide) in laboratory models to investigate its effects on GABAergic neurotransmission, BDNF gene expression, and cytokine modulation.
How does Selank differ structurally from native tuftsin?
Selank consists of the native tetrapeptide sequence of tuftsin (Thr-Lys-Pro-Arg) extended at the C-terminus with a Pro-Gly-Pro (PGP) tripeptide. This modification dramatically increases resistance to enzymatic cleavage while preserving immunomodulatory and neuroactive signaling.
What analytical methods are used to verify Selank purity?
PX1 Research verifies Selank purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity (>98%) and Mass Spectrometry (MS) to verify molecular mass and sequence identity. Every lot also undergoes Limulus Amebocyte Lysate (LAL) testing for endotoxins.
How should lyophilized Selank be stored upon receipt?
Lyophilized Selank should be stored at -20°C for short-to-medium term storage or -80°C for long-term preservation, protected from light and moisture. Upon reconstitution, liquid aliquots should be frozen to avoid repeated freeze-thaw cycles.
What is the primary mechanism of action demonstrated by Selank in animal models?
Preclinical studies demonstrate that Selank acts as an allosteric modulator of GABA-A receptors, alters monoamine (serotonin and dopamine) metabolism, increases hippocampal BDNF mRNA expression, and regulates Th1/Th2 cytokine balance.
Can Selank be reconstituted in standard phosphate-buffered saline (PBS)?
Yes. For in vitro or in vivo cell-based assays where benzyl alcohol is undesirable, sterile PBS (pH 7.4) is a suitable solvent. For extended multi-use liquid storage, sterile bacteriostatic water is typically preferred.
Where is PX1 Research Selank manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and tested by ISO 17025 accredited laboratories. Orders ship directly from our California and Arizona fulfillment centers with same-day shipping on weekday orders.
Is Selank approved for human consumption or therapeutic use?
No. Selank supplied by PX1 Research is strictly sold as a research compound for laboratory research use only. It is not intended for human or veterinary use, clinical therapy, or diagnostic applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.